Bluebird Bio signs Medicaid outcomes-based agreement for Lyfgenia

Bluebird Bio announced it has signed its first Medicaid outcomes-based agreement for Lyfgenia with the state of Michigan. Lyfgenia is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events. Approximately 50% of individuals living with sickle cell disease in the U.S. are insured by Medicaid. Bluebird is in ongoing discussions with more than 15 Medicaid agencies representing 80% of Medicaid-insured individuals in the U.S. Additionally, Bluebird has signed multiple outcomes-based agreements for Lyfgenia with national commercial payer organizations representing dozens of downstream plans and covering approximately 200M U.S. lives. Bluebird is also engaged with the Center for Medicare and Medicaid Innovation on its Cell and Gene Therapy Access Demonstration Model, which is anticipated to start in 2025.